Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Conditions
Brief summary
This study evaluates the prevalence of cannabis withdrawal and the clinical manifestations of cannabis withdrawal syndrome in patients hospitalized for BMT or CAR-T therapy.
Interventions
OTHERNon-Interventional Study
Non-interventional study
Sponsors
Mayo Clinic
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* All adult patients admitted for BMT or CAR-T therapy
Exclusion criteria
* Individuals unable to provide informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of cannabis withdrawal | Up to 1 year | Descriptive statistics will be utilized to summarize cannabis withdrawal prevalence. |
| Severity of withdrawal symptoms | Daily for first 4 days of hospitalization | Assessed by the Cannabis Withdrawal Scale (CWS), a self-report instrument used measures the intensity of 19 cannabis withdrawal symptoms over the last 24 hours. Each item is rated on a 10-point Likert scale where 0=not al all and 10=extremely. Items are rated twice, first for intensity of symptom and then for negative impact on daily activity. Withdrawal symptom scores range from 0 to 190, with higher scores reflecting greater intensity of withdrawal symptoms. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mortality Rate | Up to 1 year | Assessed for all-cause, in-hospital, and post-hospitalization mortality rates by review of the electronic medical record. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATOROsama A. Abulseoud, MD
Mayo Clinic
PRINCIPAL_INVESTIGATORSondra Schultz, MD
Mayo Clinic
Outcome results
None listed